Daniel Rieger is a doctoral researcher at CN Bio Innovations Ltd. as part of the MSCA consortium for the Horizon Europe Doctoral Networks Programme. He began his academic career by completing a bachelor’s programme in electrical and information technology at the Technical University Munich, followed by his graduation in a master’s programme in biomedical engineering at the Technical University Vienna with a specialisation in signals and instrumentation, with a focus on organ-on-a-chip applications using microfluidic principles. During his master’s thesis, he developed a sensor-integrated organ-on-chip platform and investigated size-dependent effects on the neural differentiation of P19 embryonal carcinoma embryoid bodies as a promising in vitro model for the investigation of human neurogenesis. There he gained in-depth knowledge about chip production process technologies in the cleanroom, live-cell microarray applications, biochip and organ-on-a-chip technologies. In the pursuit of following an academic career as an interdisciplinary researcher in the biomedical field with an extensive background in life sciences and engineering principles, he decided to apply his skillset for the MELOMANES project dedicated to the development of novel therapeutic treatments of metastatic melanoma.
At CN Bio, he will focus on developing a 3D perfused multi-tissue model with organotypic features as a disease model for the preclinical testing for a combined nanomedicine, making use of the company’s established PhysioMimix® platform and extensive expertise in the field of microphysiological systems.
